Journal of the American Academy of Child & Adolescent Psychiatry
Volume 49, Issue 4 , Pages 378-387 , April 2010

Suggestive Linkage of the Child Behavior Checklist Juvenile Bipolar Disorder Phenotype to 1p21, 6p21, and 8q21

  • Alysa E. Doyle, Ph.D.

      Affiliations

    • Harvard Medical School
    • Psychiatric and Neurodevelopmental Genetics Unit in the Center for Human Genetics Research at Massachusetts General Hospital (MGH)
    • Pediatric Psychopharmacology Unit at MGH
    • Corresponding Author InformationCorrespondence to Dr. Alysa E. Doyle, MGH WRN 705, 55 Fruit Street, Boston MA 02114
    • ,
  • Joseph Biederman, M.D.

      Affiliations

    • Harvard Medical School
    • Pediatric Psychopharmacology Unit at MGH
    • ,
  • Manuel A.R. Ferreira, Ph.D.

      Affiliations

    • Queensland Institute of Medical Research
    • ,
  • Patricia Wong, B.A.

      Affiliations

    • Pediatric Psychopharmacology Unit at MGH
    • ,
  • Jordan W. Smoller, M.D., Sc.D.

      Affiliations

    • Harvard Medical School
    • Psychiatric and Neurodevelopmental Genetics Unit in the Center for Human Genetics Research at Massachusetts General Hospital (MGH)
    • ,
  • Stephen V. Faraone, Ph.D.

      Affiliations

    • SUNY Upstate Medical University

,Accepted 19 January 2010.

References 

  1. Coyle JT, Pine DS, Charney DS, et al. Depression and Bipolar Support Alliance consensus statement on the unmet needs in diagnosis and treatment of mood disorders in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2003;42:1494–1503
  2. Goldstein TR, Birmaher B, Axelson D, et al. History of suicide attempts in pediatric bipolar disorder: factors associated with increased risk. Bipolar Disord. 2005;7:525–535
  3. Meyer SE, Carlson GA, Wiggs EA, et al. A prospective study of the association among impaired executive functioning, childhood attentional problems, and the development of bipolar disorder. Dev Psychopathol. 2004;16:461–476
  4. Demeter CA, Townsend LD, Wilson M, Findling RL. Current research in child and adolescent bipolar disorder. Dialogues Clin Neurosci. 2008;10:215–228
  5. Borchardt CM, Bernstein GA. Comorbid disorders in hospitalized bipolar adolescents compared with unipolar depressed adolescents. Child Psychiatry Hum Develop. 1995;26:11–18
  6. West S, McElroy S, Strakowski S, Keck P, McConville B. Attention deficit hyperactivity disorder in adolescent mania. Am J Psychiatry. 1995;152:271–273
  7. Wozniak J, Biederman J, Kiely K, et al. Mania-like symptoms suggestive of childhood onset bipolar disorder in clinically referred children. J Am Acad Child Adolesc Psychiatry. 1995;34:867–876
  8. Baroni A, Lunsford JR, Luckenbaugh DA, Towbin KE, Leibenluft E. Practitioner review: the assessment of bipolar disorder in children and adolescents. J Child Psychol Psychiatry. 2009;50:203–215
  9. McClellan J, Kowatch R, Findling RL. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:107–125
  10. Achenbach TM. Manual for the Child Behavior Checklist/4-18 and the 1991 Profile. Burlington, VT: University of Vermont, Department of Psychiatry; 1991;
  11. Biederman J. Developmental subtypes of juvenile bipolar disorder. Harvard Rev Psychiatry. 1995;3:227–230
  12. Carlson G, Loney J, Salisbury H, Volpe R. Young referrred boys with DICA-P manic symptoms vs. two comparison groups. J Affect Disord. 1998;51:113–122
  13. Dienes KA, Chang KD, Blasey CM, Adleman NE, Steiner H. Characterization of children of bipolar parents by parent report CBCL. J Psychiatr Res. 2002;36:337–345
  14. Geller B, Warner K, Williams M, Zimerman B. Prepubertal and young adolescent bipolarity versus ADHD: assessment and validity using the WASH-U-KSADS, CBCL and TRF. J Affect Disord. 1998;51:93–100
  15. Hazell P, Lewin T, Carr V. Confirmation that Child Behavior Checklist clinical scales discriminate juvenile mania from attention deficit hyperactivity disorder. J Paediatr Child Health. 1999;35:199–203
  16. Wals M, Hillegers MH, Reichart CG, et al. Prevalence of psychopathology in children of a bipolar parent. J Am Acad Child Adolesc Psychiatry. 2001;40:1094–1102
  17. Giles LL, DelBello MP, Stanford KE, Strakowski SM. Child behavior checklist profiles of children and adolescents with and at high risk for developing bipolar disorder. Child Psychiatry Hum Dev. 2007;38:47–55
  18. Mick E, Biederman J, Pandina G, Faraone SV. A preliminary meta-analysis of the Child Behavior Checklist in pediatric bipolar disorder. Biol Psychiatry. 2003;53:1021–1027
  19. Faraone SV, Althoff RR, Hudziak JJ, Monuteaux MC, Biederman J. The CBCL predicts DSM bipolar disorder in children: a receiver operating characteristic curve analysis. Bipolar Disord. 2005;7:518–524
  20. Kahana SY, Youngstrom E, Findling RL, Calabrese J. Employing parent, teacher, and yourth self-report checklists in identifying pediatric bipolar spectrum disorders: an examination of diagnostic accuracy and clinical utility. J Child Adolesc Psychopharmacol. 2003;13:471–488
  21. Biederman J, Petty CR, Monuteaux MC, et al. The Child Behavior Checklist–Pediatric Bipolar Disorder profile predicts a subsequent diagnosis of bipolar disorder and associated impairments in ADHD youth growing up: a longitudinal analysis. J Clin Psychiatry. 2009;70:732–740
  22. Volk HE, Todd RD. Does the Child Behavior Checklist Juvenile Bipolar Disorder phenotype identify bipolar disorder?. Biol Psychiatry. 2007;62:115–120
  23. Meyer SE, Carlson GA, Youngstrom E, et al. Long-term outcomes of youth who manifested the CBCL–Pediatric Bipolar Disorder phenotype during childhood and/or adolescence. J Affect Disord. 2009;113:227–235
  24. Holtmann M, Bolte S, Goth K, et al. Prevalence of the Child Behavior Checklist–Pediatric Bipolar Disorder phenotype in a German general population sample. Bipolar Disord. 2007;9:895–900
  25. Youngstrom E, Youngstrom JK, Starr M. Bipolar diagnoses in community mental health: Achenbach Child Behavior Checklist profiles and patterns of comorbidity. Biol Psychiatry. 2005;58:569–575
  26. Diler RS, Birmaher B, Axelson D, et al. The Child Behavior Checklist (CBCL) and the CBCL-bipolar phenotype are not useful in diagnosing pediatric bipolar disorder. J Child Adolesc Psychopharmacol. 2009;19:23–30
  27. Hudziak J, Althoff RR, Rettew DC, Derks EM, Faraone SV. The prevalence and genetic architecture of CBCL-juvenile bipolar disorder. Biol Psychiatry. 2005;58:562–568
  28. Boomsma DI, Rebollo I, Derks EM, et al. Longitudinal stability of the CBCL-juvenile bipolar disorder phenotype: a study in Dutch twins. Biol Psychiatry. 2006;60:912–920
  29. Althoff RR, Rettew DC, Faraone SV, Boomsma DI, Hudziak JJ. Latent class analysis shows strong heritability of the CBCL-juvenile bipolar phenotype. Biol Psychiatry. 2006;60:903–911
  30. McGough JJ, Loo SK, McCracken JT, et al. CBCL Pediatric bipolar disorder profile and ADHD: comorbidity and quantitative trait loci analysis. J Am Acad Child Adolesc Psychiatry. 2008;47:1151–1157
  31. Abou Jamra R, Fuerst R, Kaneva R, et al. The first genomewide interaction and locus-heterogeneity linkage scan in bipolar affective disorder: strong evidence of epistatic effects between loci on chromosomes 2q and 6q. Am J Hum Genet. 2007;81:974–986
  32. Faraone SV, Doyle AE, Lasky-Su J, et al. Linkage analysis of attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet. 2007;147B:1387–1391
  33. Doyle AE, Ferreira MA, Sklar PB, et al. Multivariate genomewide linkage scan of neurocognitive traits and ADHD symptoms: suggestive linkage to 3q13. Am J Med Genet B Neuropsychiatr Genet. 2008;147B:1399–1411
  34. Orvaschel H. Schedule for Affective Disorder and Schizophrenia for School-Age Children Epidemiologic Version. 5th Edition ed.. Ft. Lauderdale: Nova Southeastern University, Center for Psychological Studies; 1994;
  35. Achenbach TM, McConaughy SH. Empirically Based Assessment of Child and Adolescent Psychopathology: Practical Applications. Newbury Park: Sage Publications; 1987;
  36. Breton J, Bergeron L, Valla J, et al. Do children aged 9 through 11 years understand the DISC version 2.25 questions?. J Am Acad Child Adolesc Psychiatry. 1995;34:946–956
  37. Edelbrock C, Costello AJ, Dulcan MK, Kalas R, Conover NC. Age differences in the reliability of the psychiatric interview of the child. Child Develop. 1985;56:265–275
  38. Schwab-Stone M, Fallon T, Briggs M, Crowther B. Reliability of diagnostic reporting for children aged 6–11 years: a test-retest study of the Diagnostic Interview Schedule for Children–Revised. Am J Psychiatry. 1994;151:1048–1054
  39. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders—Clinician Version (SCID-CV). Washington, DC: American Psychiatric Press; 1997;
  40. Leckman JF, Sholomskas D, Thompson D, Belanger A, Weissman MM. Best estimate of lifetime psychiatric diagnosis: a methodological study. Arch Gen Psychiatry. 1982;39:879–883
  41. Wechsler D. Manual for the Wechsler Intelligence Scale for Children—Third Edition. San Antonio: Psychological Corporation, Harcourt Brace Jovanovich; 1991;
  42. Wechsler D. Wechsler Adult Intelligence Scale III. [manual] 3rd ed.. San Antonio, TX: Psychological Corporation; 1997;
  43. Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in general pedigrees. Am J Hum Genet. 1998;62:1198–1211
  44. Kruglyak L, Lander ES. High-resolution genetic mapping of complex traits. Am J Hum Genet. 1995;56:1212–1223
  45. Sklar P, Smoller JW, Fan J, et al. Whole-genome association study of bipolar disorder. Mol Psychiatry. 2008;13:558–569
  46. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447:661–678
  47. Arinami T, Ohtsuki T, Ishiguro H, et al. Genomewide high-density SNP linkage analysis of 236 Japanese families supports the existence of schizophrenia susceptibility loci on chromosomes 1p, 14q, and 20p. Am J Hum Genet. 2005;77:937–944
  48. Brzustowicz LM, Hodgkinson KA, Chow EW, Honer WG, Bassett AS. Location of a major susceptibility locus for familial schizophrenia on chromosome 1q21-q22. Science. 2000;288:678–682
  49. Risch N, Spiker D, Lotspeich L, et al. A genomic screen of autism: evidence for a multilocus etiology. Am J Hum Genet. 1999;65:493–507
  50. Lewis CM, Levinson DF, Wise LH, et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia. Am J Hum Genet. 2003;73:34–48
  51. Sullivan PF, Lin D, Tzeng JY, et al. Genomewide association for schizophrenia in the CATIE study: results of stage 1. Mol Psychiatry. 2008;13:570–584
  52. Marshall CR, Noor A, Vincent JB, et al. Structural variation of chromosomes in autism spectrum disorder. Am J Hum Genet. 2008;82:477–488
  53. Neale BM, Lasky-Su J, Anney R, et al. Genome-wide association scan of attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet. 2008;147B:1337–1344
  54. Schwab SG, Hallmayer J, Albus M, et al. A genome-wide autosomal screen for schizophrenia susceptibility loci in 71 families with affected siblings: support for loci on chromosome 10p and 6. Mol Psychiatry. 2000;5:638–649
  55. Bierut LJ, Stitzel JA, Wang JC, et al. Variants in nicotinic receptors and risk for nicotine dependence. Am J Psychiatry. 2008;165:1163–1171
  56. Suarez BK, Hampe CL, Van Eerdewegh P. Problems of replicating linkage claims in psychiatry. In:  Gershon ES,  Cloninger CR,  Barrett JE editor. Genetic Approaches in Mental Disorders. Washington, DC: American Psychiatric Press; 1994;p. 23–46
  57. Elashoff M, Higgs BW, Yolken RH, et al. Meta-analysis of 12 genomic studies in bipolar disorder. J Mol Neurosci. 2007;31:221–243
  58. Moskvina V, Craddock N, Holmans P, et al. Gene-wide analyses of genome-wide association data sets: evidence for multiple common risk alleles for schizophrenia and bipolar disorder and for overlap in genetic risk. Mol Psychiatry. 2009;14:252–260
  59. Burbach JP, van der Zwaag B. Contact in the genetics of autism and schizophrenia. Trends Neurosci. 2009;32:69–72
  60. Rzhetsky A, Wajngurt D, Park N, Zheng T. Probing genetic overlap among complex human phenotypes. Proc Natl Acad Sci U S A. 2007;104:11694–11699
  61. Tomppo L, Hennah W, Lahermo P, et al. Association between genes of Disrupted in Schizophrenia 1 (DISC1) interactors and schizophrenia supports the role of the DISC1 pathway in the etiology of major mental illnesses. Biol Psychiatry. 2009;65:1055–1062
  62. Ayer L, Althoff R, Ivanova M, et al. Child Behavior Checklist Juvenile Bipolar Disorder (CBCL-JBD) and CBCL Posttraumatic Stress Problems (CBCL-PTSP) scales are measures of a single dysregulatory syndrome. J Child Psychol Psychiatry. 2009;50:1291–1300
  63. Mick E, Faraone SV. Family and genetic association studies of bipolar disorder in children. Child Adolesc Psychiatr Clin North Am. 2009;18:441–453x
  64. Doyle AE, Faraone S. Familial links between ADHD, conduct disorder and bipolar disorder. Curr Psychiatry Rep. 2002;4:146–152

 This article was reviewed under and accepted by Ad Hoc Editor James F. Leckman, M.D..

 This work was supported by R01HD37694 to Dr. Faraone and K08MH66072 to Dr. Doyle. Portions of this work were presented at the MGH-Ryan Licht Sang Pediatric Bipolar Disorder Foundation Conference, March 27, 2009, Cambridge, MA.

 Disclosure: Dr. Doyle has received research funding from the National Institute of Mental Health, Harvard Medical School, and the Stanley Foundation. She received consulting fees from Pfizer Inc in 2007 and speaker's fees from Reed Education in 2008. Dr. Biederman currently receives research support from the following sources: Alza, AstraZeneca, Bristol Myers Squibb, Eli Lilly and Co., Janssen Pharmaceuticals Inc., McNeil, Merck, Organon, Otsuka, Shire, National Institute of Mental Health (NIMH), and the National Institute of Child Health and Human Development (NICHD). In 2009, Dr. Biederman received a speaker's fee from the following sources: Fundacion Areces, Medice Pharmaceuticals, and the Spanish Child Psychiatry Association. In previous years, Dr. Biederman received research support, consultation fees, or speaker's fees for/from the following additional sources: Abbott, AstraZeneca, Celltech, Cephalon, Eli Lilly and Co., Esai, Forest, Glaxo, Gliatech, Janssen, McNeil, the National Alliance for Research on Schizophrenia and Depression (NARSAD), National Institute on Drug Abuse (NIDA), New River, Novartis, Noven, Neurosearch, Pfizer, Pharmacia, The Prechter Foundation, Shire, The Stanley Foundation, UCB Pharma, Inc., and Wyeth. Dr. Faraone, in the past year, has received consulting fees and has been on Advisory Boards for Eli Lilly and Shire and has received research support from Eli Lilly, Pfizer, Shire, and the National Institutes of Health. In previous years, he has received consulting fees or has been on Advisory Boards or has been a speaker for the following sources: Shire, McNeil, Janssen, Novartis, Pfizer, and Eli Lilly. In previous years he has received research support from Eli Lilly, Shire, Pfizer, and the National Institutes of Health. Drs. Ferreira and Smoller, and Ms Wong report no biomedical financial interests or potential conflicts of interest.

 This article is discussed in an editorial by Dr. Robert Althoff on page 302.

PII: S0890-8567(10)00084-5

doi: 10.1016/j.jaac.2010.01.008

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 49, Issue 4 , Pages 378-387 , April 2010

Article Tools

* Image Usage & Resolution